Prognostic factors in patients presenting with pleural effusion revealing malignancy

Respiration

Volumn 87, Issue 4, 2014, Pages 311-316

  Anevlavis, Stavros ^a   Kouliatsis, George ^a   Sotiriou, Ioannis ^a   Koukourakis, Michael I ^b   Archontogeorgis, Kostas ^a   Karpathiou, Georgia ^c   Giatromanolaki, Alexandra ^c   Froudarakis, Marios E ^a  

^a DEMOCRITUS UNIVERSITY OF THRACE   (Greece)

^b Radiation Oncology   (Greece)

^c DEMOCRITUS UNIVERSITY OF THRACE   (Greece)

Author keywords

Factor; Malignant pleural effusion; Prognosis; Survival; Thoracoscopy

Indexed keywords

ADULT; AGED; ARTICLE; BREAST CARCINOMA; CANCER DIAGNOSIS; CANCER SURVIVAL; FEMALE; FOLLOW UP; HUMAN; LUNG CARCINOMA; MAJOR CLINICAL STUDY; MALE; MALIGNANT PLEURA EFFUSION; MESOTHELIOMA; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; REGRESSION ANALYSIS; SURVIVAL TIME; THORACOSCOPY; EPIDEMIOLOGY; GREECE; LEUKOCYTE COUNT; MIDDLE AGED; MORTALITY; PLEURAL EFFUSION, MALIGNANT; PROSPECTIVE STUDY; VERY ELDERLY; CANCER PROGNOSIS; HISTOPATHOLOGY; LYMPHOMA; NEUTROPHIL COUNT; NEUTROPHIL LYMPHOCYTE RATIO; NON SMALL CELL LUNG CANCER; OVARY CARCINOMA; PH; PLEURA EFFUSION; PLEURODESIS; PRIMARY TUMOR; SMALL CELL LUNG CANCER;

ADULT; AGED; AGED, 80 AND OVER; FEMALE; GREECE; HUMANS; LEUKOCYTE COUNT; MALE; MIDDLE AGED; PLEURAL EFFUSION, MALIGNANT; PROGNOSIS; PROSPECTIVE STUDIES; THORACOSCOPY;

EID: 84898600724     PISSN: 00257931     EISSN: 14230356     Source Type: Journal    
DOI: 10.1159/000356764     Document Type: Article

References (37)

1. Froudarakis ME: Diagnostic work-up of pleural effusions. Respiration 2008; 75: 4-13.
2. Froudarakis ME: Pleural diseases in the molecular era: time for more answers -introduction. Respiration 2012; 83: 2-4.
3. Chernow B, Sahn SA: Carcinomatous involvement of the pleura: an analysis of 96 patients. Am J Med 1977; 63: 695-702.
4. Burrows CM, Mathews WC, Colt HG: Predicting survival in patients with recurrent symptomatic malignant pleural effusions: an assessment of the prognostic values of physiologic, morphologic, and quality of life measures of extent of disease. Chest 2000; 117: 73-78.
5. Zimmer PW, Hill M, Casey K, Harvey E, Low DE: Prospective randomized trial of talc slurry vs. Bleomycin in pleurodesis for symptomatic malignant pleural effusions. Chest 1997; 112: 430-434.
6. Rodriguez-Panadero F, Janssen JP, Astoul P: Thoracoscopy: general overview and place in the diagnosis and management of pleural effusion. Eur Respir J 2006; 28: 409-422.
7. Good JT Jr, Taryle DA, Sahn SA: The pathogenesis of low glucose, low pH malignant effusions. Am Rev Respir Dis 1985; 131: 737-741.
8. Sahn SA, Good JT Jr: Pleural fluid pH in malignant effusions: diagnostic, prognostic, and therapeutic implications. Ann Intern Med 1988; 108: 345-349.
9. Rodriguez-Panadero F, Lopez Mejias J: Low glucose and pH levels in malignant pleural effusions: diagnostic significance and prognostic value in respect to pleurodesis. Am Rev Respir Dis 1989; 139: 663-667.
10. Sanchez-Armengol A, Rodriguez-Panadero F: Survival and talc pleurodesis in metastatic pleural carcinoma, revisited: report of 125 cases. Chest 1993; 104: 1482-1485.
11. Rodriguez-Panadero F, Lopez-Mejias J: Survival time of patients with pleural metastatic carcinoma predicted by glucose and pH studies. Chest 1989; 95: 320-324.
12. Froudarakis ME, Klimathianaki M, Pougounias M: Systemic inflammatory reaction after thoracoscopic talc poudrage. Chest 2006; 129: 356-361.
13. Steger V, Mika U, Toomes H, Walker T, Engel C, Kyriss T, Ziemer G, Friedel G: Who gains most? A 10-year experience with 611 thoracoscopic talc pleurodeses. Ann Thorac Surg 2007; 83: 1940-1945.
14. Buccheri G, Ferrigno D, Vola F: Carcinoembryonic antigen (CEA), tissue polypeptide antigen (TPA) and other prognostic indicators in squamous cell lung cancer. Lung Cancer 1993; 10: 21-33.
15. Martinez-Moragon E, Aparicio J, Sanchis J, Menendez R, Cruz Rogado M, Sanchis F: Malignant pleural effusion: prognostic factors for survival and response to chemical pleurodesis in a series of 120 cases. Respiration 1998; 65: 108-113.
16. Stanley KE: Prognostic factors for survival in patients with inoperable lung cancer. J Natl Cancer Inst 1980; 65: 25-32.
17. Bielsa S, Salud A, Martinez M, Esquerda A, Martin A, Rodriguez-Panadero F, Porcel JM: Prognostic significance of pleural fluid data in patients with malignant effusion. Eur J Intern Med 2008; 19: 334-339.
18. Sculier JP, Chansky K, Crowley JJ, Van Meerbeeck J, Goldstraw P: The impact of additional prognostic factors on survival and their relationship with the anatomical extent of disease expressed by the 6th edition of the TNM classification of malignant tumors and the proposals for the 7th edition. J Thorac Oncol 2008; 3: 457-466.
19. Paesmans M, Sculier JP, Libert P, Bureau G, Dabouis G, Thiriaux J, Michel J, Van Cutsem O, Sergysels R, Mommen P, et al: Prognostic factors for survival in advanced non-smallcell lung cancer: univariate and multivariate analyses including recursive partitioning and amalgamation algorithms in 1,052 patients -The European Lung Cancer Working Party. J Clin Oncol 1995; 13: 1221-1230.
20. Schmidt H, Bastholt L, Geertsen P, Christensen IJ, Larsen S, Gehl J, von der Maase H: Elevated neutrophil and monocyte counts in peripheral blood are associated with poor survival in patients with metastatic melanoma: a prognostic model. Br J Cancer 2005; 93: 273-278.
21. Atzpodien J, Royston P, Wandert T, Reitz M: Metastatic renal carcinoma comprehensive prognostic system. Br J Cancer 2003; 88: 348-353.
22. Fogar P, Sperti C, Basso D, Sanzari MC, Greco E, Davoli C, Navaglia F, Zambon CF, Pasquali C, Venza E, Pedrazzoli S, Plebani M: Decreased total lymphocyte counts in pancreatic cancer: an index of adverse outcome. Pancreas 2006; 32: 22-28.
23. Adzic TN, Pesut DP, Nagorni-Obradovic LM, Stojsic JM, Vasiljevic MD, Bouros D: Clinical features of lung cancer in patients with connective tissue diseases: a 10-year hospital based study. Respir Med 2008; 102: 620-624.
24. Lissoni P, Brivio F, Fumagalli L, Messina G, Ghezzi V, Frontini L, Giani L, Vaghi M, Ardizzoia A, Gardani GS: Efficacy of cancer chemotherapy in relation to the pretreatment number of lymphocytes in patients with metastatic solid tumors. Int J Biol Markers 2004; 19: 135-140.
25. Walsh SR, Cook EJ, Goulder F, Justin TA, Keeling NJ: Neutrophil- lymphocyte ratio as a prognostic factor in colorectal cancer. J Surg Oncol 2005; 91: 181-184.
26. Halazun KJ, Aldoori A, Malik HZ, Al-Mukhtar A, Prasad KR, Toogood GJ, Lodge JP: Elevated preoperative neutrophil to lymphocyte ratio predicts survival following hepatic resection for colorectal liver metastases. Eur J Surg Oncol 2008; 34: 55-60.
27. Hirashima M, Higuchi S, Sakamoto K, Nishiyama T, Okada H: The ratio of neutrophils to lymphocytes and the phenotypes of neutrophils in patients with early gastric cancer. J Cancer Res Clin Oncol 1998; 124: 329-334.
28. Sarraf KM, Belcher E, Raevsky E, Nicholson AG, Goldstraw P, Lim E: Neutrophil/lymphocyte ratio and its association with survival after complete resection in non-small cell lung cancer. J Thorac Cardiovasc Surg 2009; 137: 425-428.
29. Bouros D, Froudarakis M, Siafakas NM: Pleurodesis: everything flows. Chest 2000; 118: 577-579.
30. Rodriguez-Panadero F: Medical thoracoscopy. Respiration 2008; 76: 363-372.
31. Rodriguez-Panadero F, Montes-Worboys A: Mechanisms of pleurodesis. Respiration 2012; 83: 91-98.
32. Bilaceroglu S, Cagirici U, Perim K, Ozacar R: Corynebacterium parvum pleurodesis and survival is not significantly influenced by pleural pH and glucose level. Monaldi Arch Chest Dis 1998; 53: 14-22.
33. Foresti V, Scolari N, Villa A, Parisio E, De Filippi G, Guareschi G: Malignant pleural effusions: meaning of pleural-fluid pH determination. Oncology 1990; 47: 62-64.
34. Heffner JE, Nietert PJ, Barbieri C: Pleural fluid pH as a predictor of survival for patients with malignant pleural effusions. Chest 2000; 117: 79-86.
35. Froudarakis ME: Pleural effusion in lung cancer: more questions than answers. Respiration 2012; 83: 367-376.
36. Goldstraw P, Crowley J, Chansky K, Giroux DJ, Groome PA, Rami-Porta R, Postmus PE, Rusch V, Sobin L: The IASLC lung cancer staging project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM classification of malignant tumours. J Thorac Oncol 2007; 2: 706-714.
37. Astoul P, Roca E, Galateau-Salle F, Scherpereel A: Malignant pleural mesothelioma: from the bench to the bedside. Respiration 2012; 83: 481-493.